Billions of dollars in annual revenue and the health of millions of patients are at stake in a drug industry battle over who ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

The agreement covering Zealand's compound petrelintide, signals renewed efforts by Roche to catch up with obesity market leaders Novo Nordisk and Eli Lilly. Under the accord, Zealand will receive ...

Follow us on Facebook and join our Telegram channel for the latest updates. Hyphens Pharma has gained exclusive rights to commercialise an autoinjector pen for the treatment of rheumatoid arthritis, ...

Viking Therapeutics' stock declined by 37% following a downgrade to "hold" in December, anticipating competitive pressures from Novo Nordisk's ... VK2735 with an auto-injector could delay ...

Viking Therapeutics (VKTX) stock in focus as the company secures a major production deal with CordenPharma for VK2735, its obesity drug candidate. Read more here.